SWIFTWATER, Pa. - Led by impressive gains in vaccine sales by Sanofi Pasteur, Sanofi, the parent company of Sanofi Pasteur which is headquartered in Swiftwater, Monroe County, Pa., again reported ...

Pediatr Infect Dis J. 2016;35(1):81-93. MenACWY-CRM was supplied in 2 vials: 1 vial of lyophilized powder containing 10 μg of MenA oligosaccharide conjugated to CRM 197 and a second liquid ...

The vaccine used in the RV144 trial is a combination of two vaccines given in a 'prime–boost' strategy: ALVAC-HIV from Sanofi Pasteur (Swiftwater, PA, USA) and AIDSVAX from VaxGene (San ...

The vaccine being tested in this trial is manufactured by Sanofi Pasteur in Swiftwater, Pa., in the same manner as its licensed seasonal vaccine, which is used every year in millions of children ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...

The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one of the world’s largest producers of vaccinations for a variety of conditions, including tetanus ...

The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...

L’Oreal OR0.83%increase; green up pointing triangle will sell part of its stake in Sanofi SAN-0.46%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...